Skip to main content

Fungal Keratitis

3
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Innovation Pharmaceuticals
1 program
1
povidone-iodine 1.25% ophthalmic solutionPhase 3
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
povidone-iodine 1.25% ophthalmic solutionPhase 31 trial
Active Trials
NCT00516399Terminated78Est. Dec 2010
IVIEW Therapeutics
IVIEW TherapeuticsNJ - Cranbury
1 program
1
IVIEW-1201Phase 21 trial
Active Trials
NCT06463678Not Yet Recruiting60Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Angeles Therapeuticspovidone-iodine 1.25% ophthalmic solution
IVIEW TherapeuticsIVIEW-1201

Clinical Trials (2)

Total enrollment: 138 patients across 2 trials

NCT00516399Angeles Therapeuticspovidone-iodine 1.25% ophthalmic solution

A Clinical Trial of the Treatment of Fungal Corneal Ulcers With Povidone-Iodine

Start: Mar 2008Est. completion: Dec 201078 patients
Phase 3Terminated

Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis

Start: Aug 2026Est. completion: Dec 202760 patients
Phase 2Not Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.